Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

What Was Tested

The paper reports a study of Survodutide and Glucagon, published as a randomized controlled trial.

This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.

Biomarker responses were analysed using mixed models for repeated measures and regression analysis to assess the impact of bodyweight changes.

Why It Was Studied

Trial 1404-0002, ClinicalTrials.gov identifier: NCT04153929; EudraCT number: 2019-002390-60.

Trial 1404-0036, ClinicalTrials.gov identifier: NCT04667377; EudraCT number: 2020-002479-37.

Who Took Part

The study group was 0002 participants.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.

Trial 1404-0036 randomised 387 participants with overweight/obesity and normoglycaemia to receive survodutide or placebo for 46 weeks.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Survodutide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Survodutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Survodutide could be set against what happens without it.

The methods mention a period of 16 weeks.

Descriptive statistics were derived from both trials.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Insulin Resistance, Insulin-Secreting Cells, Biomarkers, Obesity, Hypoglycemic Agents and Overweight.

Author keywords: GLP‐1, beta‐cell function, glucagon, insulin sensitivity, survodutide and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Survodutide and Glucagon in 0002 participants over 16 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Survodutide compound page and the Glucagon compound page, all human trials.